Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.

Trial Profile

Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Neihulizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AbGenomics Corporation
  • Most Recent Events

    • 26 Apr 2016 Results (n=20) published in an AbGenomics International media release.
    • 28 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 28 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Jul 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top